Medications

Apixaban not superior to standard care after TAVR

The blood thinner apixaban was not superior to standard of care following transcatheter aortic valve replacement (TAVR), according to findings from a new trial called ATLANTIS presented at the American College of Cardiology's ...

Cardiology

Results from the COBRA-REDUCE trial reported

For patients undergoing percutaneous coronary intervention (PCI) that also require oral anticoagulation, treatment with a nanotechnology polymer-coated stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding ...

page 2 from 5